Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — Q1 FY27 Earnings Presentation
38 slides from Trident Lifeline's earnings presentation, Aug 3, 2026
Slide 1: BSE filing cover letter for earnings presentation
Date: 03.08.2026 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai – 400001. Sub: Earnings Presentation-Q1 & FY27. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earn
Slide 2: Investor Presentation
Investor Presentation Trident Lifeline Limited (TLL) August 2026
Slide 3: Inside this presentation
Inside this presentation 04 06 16 25 27 Earnings About Our right Investment Financial update us to win rationale overview
Slide 4: Earnings update
04 Performance update and management commentary 04 Earnings update
Slide 5: Performance update and management commentary
04 | E A R N IN G S U P DA TES Performance update and management commentary Management commentary Over the past decade, our journey has been defined by disciplined investment. Our dedication toward securing approvals, building manufacturing infrastructure, creating execution capabilities, and establ
Slide 6: About us
Company overview 06 06 Our business model 08 About us Our journey 09 Our subsidiaries 10
Slide 7: Creating long term value through scalable expansion
06 | A B O UT U S : C O MP A N Y O V E R VIE W Creating long term value through scalable expansion Revenue from operations Operating profit (EBITDA) Profit after tax CAGR: 56% CAGR: 79% CAGR: 49% 129.0 28.1 19.3 87.0 14.9 10.5 44.6 8.2 6.0 5.9 31.7 6.3 3.9 21.8 2.7 FY22 FY23 FY24 FY25 FY26 FY22 FY23
Slide 8: Building a global healthcare platform
07 | A B O UT U S : C O MP A N Y O V E R VIE W Building a global healthcare platform The integrated trident ecosystem Trident at a glance Building a diversified manufacturing platform across formulations and medical devices ▪ Established in 2014 as an export-focused pharmaceutical company, building
Slide 9: An integrated model creating value across the pharmaceutical value chain
08 | A B O UT U S : O U R B U S IN E SS MO D E L An integrated model creating value across the pharmaceutical value chain Our operational excellence and OPERATIONAL VALUE CHAIN Procurement Manufacturing Exports strategic enablers create a self-reinforcing cycle of growth Consolidated manufacturing ▪
Slide 10: Building a global pharmaceutical platform
09 | A B O UT U S : O U R J O U R N EY Building a global pharmaceutical platform 2015 - 2016 2021 - 2022 2024 2025 2026 Company formation Market expansion Strategic growth Operational scale Building future pipeline ▪ Beginning of ▪ Plant approvals ▪ Commercial operation ▪ Commercial operation of ▪ C
Slide 11: TNS Pharma Private Limited
10 | A B O UT U S : O U R S U B S IDIA RY TNS Pharma Private Limited Operational metrics ▪ Manufactures high-quality tablets, capsules and dry powder Peak revenue suspension ▪ Operates under WHO-GMP standards with advanced 40 crs. infrastructure ▪ Strategic Importance: Driving capacity expansion, ma
Slide 12: Trident Mediquip Limited
11 | A B O UT U S : O U R S U B S IDIA RY Trident Mediquip Limited Operational metrics Peak revenue ▪ Manufacturing in the medical devices segment, with products such as Double Safety IV Cannulas and Air Block Mechanism 70 crs. Infusion (IFG) Sets ▪ Offers a diversified portfolio of medical devices
Slide 13: TLL Parenterals Limited
12 | A B O UT U S : O U R S U B S IDIA RY TLL Parenterals Limited Operational metrics Peak revenue ▪ Dedicated manufacturing arm for injectable pharmaceutical products. 200 crs. ▪ Newly incorporated entities with operations yet to commence, revenue contribution expected from FY27 onwards Peak utiliz
Slide 14: TLL Wellness Limited
13 | A B O UT U S : O U R S U B S IDIA RY TLL Wellness Limited Operational metrics Peak revenue ▪ Operates in herbal products and nutraceutical supplements, catering to the growing demand for wellness solutions 10 crs. ▪ Product development was undertaken during FY26, with revenue generation expecte
Slide 15: TLL Elements Limited
14 | A B O UT U S : O U R S U B S IDIA RY TLL Elements Limited Operational metrics Peak revenue ▪ Operates in the manufacturing, trading, and distribution of a comprehensive range of cosmetic products 20 crs. ▪ Introduced its cosmetic product portfolio under the "YES" brand in FY26 ▪ Well positioned
Slide 16: Our right to win
Extensive product portfolio 16 Our core asset: Registrations 17 16 In-house R&D and F&D unit How our model works 18 19 Our right to Why us 20 win Board of directors 21 Our presence 23
Slide 17: Diverse product categories delivering broad therapeutic coverage globally
16 | O U R R IG H T T O W IN : E XT E N S IV E P R O DUCT P O R T FOL IO Diverse product categories delivering broad therapeutic coverage globally Product categories Therapeutic excellence *A/ = Anti A/ Bacterial A/ Diabetic Dental Range A/ Lipidemic Drug Oral Solids Liquids Tablet, Capsule, Dry Syr
Slide 18: A strong registration base is a high-barrier asset
17 | O U R R IG H T T O W IN : O U R C O R E A S S E T - R E G IS T RA TION S A strong registration base is a high-barrier asset that creates a compounding engine for long-term value Registration platform Our compounding growth engine Value created 1.5 – 3 years Cash generation Registrations Access
Slide 19: Key driver in creating innovative, market-ready solutions
18 | O U R R IG H T T O W IN : IN -H O U SE R & D A N D F & D U N IT Key driver in creating innovative, market-ready solutions End-to-end development capabilities R&D and F&D Investment (₹ crore) Provide : 1 Key value proposition ▪ Formulation development 0.8 F&D and R&D team ▪ Process development 0
Slide 20: Building manufacturing capabilities behind validated global demand
19 | O U R R IG H T T O W IN : H O W O U R MO D E L W O R K S Building manufacturing capabilities behind validated global demand Traditional pharma model Factory built before Heavy upfront capital Customer sought Long investment-to- Risk of idle Delayed return demand exists commitment after setup re
Slide 21: Accreditation from regulatory authorities
20 | O U R R IG H T T O W IN : W H Y U S Accreditation from regulatory authorities
Slide 22: Experienced leadership driving growth, governance and long-term value creation
21 | O U R R IG H T T O W IN : B O A R D O F D IR E C TORS Experienced leadership driving growth, governance and long-term value creation Mr. Hardik Mr. Shravan Mr. Ashish Ms. Rupaben Ms. Maniya Jigishkumar Desai Harikrishna Patel Bafna Chetan Jariwala Hardik Desai Chairman Managing Director Executi
Slide 23: Diverse independent board strengthens governance and strategic oversight
22 | O U R R IG H T T O W IN : B O A R D O F D IR E C TORS Diverse independent board strengthens governance and strategic oversight Dr. Mishal Shailesh Ms. Falguni Bhavesh Ms. Smita Kiran Mr. Sachin Bhandari Patel Jariwala Davda Independent Director Independent Director Independent Director Independ
Slide 24: Built presence across multiple emerging markets
23 | O U R R IG H T T O W IN : O U R P R E S EN C E Built presence across multiple emerging markets, creating a foundation for scalable growth Share of global registrations by region Our geographic presence 1% CIS 21% Africa Deepening institutional reach and commercial Our Establishing and scaling p
Slide 25: Investment Rationale
25 Our growth drivers 25 Investment Rationale
Slide 26: Building a larger, more profitable global pharmaceutical platform
25 | G R O W TH S T R A T EG Y: O U R G R O W TH D R IV E RS Building a larger, more profitable global pharmaceutical platform Why we believe growth can sustain Value creation framework 2,534 Larger registration Portfolio expansion Manufacturing 1 Registrations Registrations pipeline platform under
Slide 27: Financial overview
Historical business performance 27 27 Revenue split across segments 29 Income Statement (standalone) 32 Financial Balance Sheet and cash flow statement (standalone) 33 overview Income Statement (consolidated) 34 Balance sheet and cash flow statement (consolidated) 35
Slide 28: Historical business performance (1/2) (standalone)
27 | F IN A N C IA L O V E R VIE W Historical business performance (1/2) (based on standalone financials) All currencies is in ₹ crores, unless otherwise mentioned Revenue from operations EBITDA Profit after tax (PAT) 51% (2YR CAG R) 33.0 66% (2YR CAGR) 1.2 60% (2YR CAGR) 28.0 1 20.0 23.0 18.0 0.8 1
Slide 29: Historical business performance (2/2) (standalone)
28 | F IN A N C IA L O V E R VIE W Historical business performance (2/2) (based on standalone financials) All currencies is in ₹ crores, unless otherwise mentioned Return on equity (ROE) Return on capital employed (ROCE) Net debt to equity ratio (D/E) 763 bps (O VER 2YR) 932 bps (O VER 2YR) 32.0% 1.
Slide 30: Revenue split across segments – FY26
29 | F IN A N C IA L O V E R VIE W Revenue split across segments – FY26 (based on consolidated financials) Tablets Capsules Others1 350% 119% 30.6 -38% 68.3 49.0 6.8 30.1 31.2 FY25 FY26 FY25 FY26 FY25 FY26 Total 48% Revenue contribution (%) 129.0 23% Tablets 87.0 36% Capsules 56% FY25 FY26 53% Other
Slide 31: Historical business performance (1/2) (consolidated)
30 | F IN A N C IA L O V E R VIE W Historical business performance (1/2) (based on consolidated financials) All currencies is in ₹ crores, unless otherwise mentioned Revenue from operations EBITDA Profit after tax (PAT) 70% (2YR CAG R) 33.0 85% (2YR CAGR) 1.2 80% (2YR CAGR) 28.0 1 1.2 23.0 20.0 0.8
Slide 32: Historical business performance (2/2) (consolidated)
31 | F IN A N C IA L O V E R VIE W Historical business performance (2/2) (based on consolidated financials) All currencies is in ₹ crores, unless otherwise mentioned Return on equity (ROE) Return on capital employed (ROCE) Net debt to equity ratio (D/E) 1,036 bps (O VER 2YR) 528 bps (O VER 2YR) 20.0
Slide 33: Income Statement and Cash flow Statement (standalone)
32 | F IN A N C IA L O V E R VIE W Income Statement (based on standalone financials) All currencies is in ₹ crores, unless otherwise mentioned Particulars Q1 FY26 Q1 FY27 YoY change FY24 FY25 FY26 YoY change Revenue from operations 18.8 26.8 43% 44.7 67.8 101.9 50% Cost of materials consumed 12.1 16
Slide 34: Balance Sheet (standalone)
33 | F IN A N C IA L O V E R VIE W Balance Sheet (based on standalone financials) All currencies is in ₹ crores, unless otherwise mentioned Equity and Liabilities FY24 FY25 FY26 Assets FY24 FY25 FY26 Share capital 11.5 11.5 11.9 Non-current assets: Reserves & surplus 41.2 54.2 83.4 Tangible assets 3
Slide 35: Income Statement and Cash flow Statement (consolidated)
34 | F IN A N C IA L O V E R VIE W Income Statement (based on consolidated financials) All currencies is in ₹ crores, unless otherwise mentioned Particulars Q1 FY26 Q1 FY27 YoY change FY24 FY25 FY26 YoY change Revenue from operations 23.6 33.7 43% 44.6 87.0 129.0 48% Cost of materials consumed 13.8
Slide 36: Balance Sheet (consolidated)
35 | F IN A N C IA L O V E R VIE W Balance Sheet (based on consolidated financials) All currencies is in ₹ crores, unless otherwise mentioned Equity and Liabilities FY24 FY25 FY26 Assets FY24 FY25 FY26 Share capital 11.5 11.5 11.9 Non-current assets: Reserves & surplus 40.4 53.0 84.7 Tangible assets
Slide 37: Safe harbor statement
Safe harbor statement Global market size (USD Bn) This presentation and the accompanying slides (the “Presentation”), which have been prepared by Trident Lifeline Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation
Slide 38: Get in Touch with Us
Get in Touch with Us For further information, please contact: Nikita Sharma Company Secretary compliance@tridentlifeline.com Our Investor Relations Partner Meeting Request Link Link Research Team Mr. Rutul Shah +91 63549 47366 +91 82002 47366 research@atlascapital.in rutul@atlascapital.in